Bioversys AG Total Liabilities
Bioversys AG total liabilities. Based on the latest financial reports, Bioversys AG (BIOV) has total liabilities worth CHF32.07 Million CHF (≈ $40.54 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Bioversys AG's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Bioversys AG (2024–2025)
Total liabilities of Bioversys AG from 2024 to 2025. This chart illustrates how Bioversys AG's total liabilities have evolved over time, based on quarterly financial data.
Bioversys AG Competitors by Total Liabilities
The table below lists competitors of Bioversys AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sahamitr Pressure Container Public Company Limited
BK:SMPC
|
Thailand | ฿496.10 Million |
|
Nordfyns Bank A/S
CO:NRDF
|
Denmark | Dkr5.00 Billion |
|
GalaxyEdge Acquisition Corporation
NYSE:GLED
|
USA | $115.66 Million |
|
Novonix Ltd ADR
NASDAQ:NVX
|
USA | $99.73 Million |
|
Future Money Acquisition Corporation
NASDAQ:FMAC
|
USA | $13.99K |
|
Li Peng Enterprise Co Ltd
TW:1447
|
Taiwan | NT$7.65 Billion |
|
LaFayette Acquisition Corp. Ordinary Share
NASDAQ:LAFA
|
USA | $4.14 Million |
|
KT Hitel Corporation. Limited
KQ:036030
|
Korea | ₩170.01 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Bioversys AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BIOV total assets.
Liquidity & Leverage Metrics
Bioversys AG Total Liabilities Ratios Explained
Bioversys AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioversys AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioversys AG (2024–2025)
The table below shows the annual total liabilities of Bioversys AG from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF30.82 Million ≈ $38.97 Million |
+26.99% |
| 2024-12-31 | CHF24.27 Million ≈ $30.69 Million |
-- |
About Bioversys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S.… Read more